Cargando…
Efavirenz reduces renal excretion of lamivudine in rats by inhibiting organic cation transporters (OCT, Oct) and multidrug and toxin extrusion proteins (MATE, Mate)
Efavirenz (EFV) is a non-nucleoside reverse transcriptase inhibitor used in first-line combination antiretroviral therapy (cART). It is usually administered with nucleoside reverse transcriptase inhibitors (NRTI), many of which are substrates of OCT uptake solute carriers (SLC22A) and MATE (SLC47A),...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095608/ https://www.ncbi.nlm.nih.gov/pubmed/30114293 http://dx.doi.org/10.1371/journal.pone.0202706 |
_version_ | 1783347970671902720 |
---|---|
author | Ceckova, Martina Reznicek, Josef Deutsch, Birgit Fromm, Martin F. Staud, Frantisek |
author_facet | Ceckova, Martina Reznicek, Josef Deutsch, Birgit Fromm, Martin F. Staud, Frantisek |
author_sort | Ceckova, Martina |
collection | PubMed |
description | Efavirenz (EFV) is a non-nucleoside reverse transcriptase inhibitor used in first-line combination antiretroviral therapy (cART). It is usually administered with nucleoside reverse transcriptase inhibitors (NRTI), many of which are substrates of OCT uptake solute carriers (SLC22A) and MATE (SLC47A), P-gp (MDR1, ABCB1), BCRP (ABCG2), or MRP2 (ABCC2) efflux transporters. The aim of this study was to evaluate the inhibitory potential of efavirenz towards these transporters and investigate its effects on the pharmacokinetics and tissue distribution of a known Oct/Mate substrate, lamivudine, in rats. Accumulation and transport assays showed that efavirenz inhibits the uptake of metformin by OCT1-, OCT2- and MATE1-expressing MDCK cells and reduces transcellular transport of lamivudine across OCT1/OCT2- and MATE1-expressing MDCK monolayers. Only negligible inhibition of MATE2-K was observed in HEK-MATE2-K cells. Efavirenz also reduced the efflux of calcein from MDCK-MRP2 cells, but had a rather weak inhibitory effect on Hoechst 33342 accumulation in MDCK-MDR1 and MDCK-BCRP cells. An in vivo pharmacokinetic interaction study in male Wistar rats revealed that intravenous injection of efavirenz or the control Oct/Mate inhibitor cimetidine significantly reduced the recovery of lamivudine in urine and greatly increased lamivudine retention in the renal tissue. Co-administration with efavirenz or cimetidine also increased the AUC(0-∞) value and reduced total body clearance of lamivudine. These data suggest that efavirenz is a potent inhibitor of OCT/Oct and MATE/Mate transporters. Consequently, it can engage in drug-drug interactions that reduce renal excretion of co-administered substrates and enhance their retention in the kidneys, potentially compromising therapeutic safety. |
format | Online Article Text |
id | pubmed-6095608 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-60956082018-08-30 Efavirenz reduces renal excretion of lamivudine in rats by inhibiting organic cation transporters (OCT, Oct) and multidrug and toxin extrusion proteins (MATE, Mate) Ceckova, Martina Reznicek, Josef Deutsch, Birgit Fromm, Martin F. Staud, Frantisek PLoS One Research Article Efavirenz (EFV) is a non-nucleoside reverse transcriptase inhibitor used in first-line combination antiretroviral therapy (cART). It is usually administered with nucleoside reverse transcriptase inhibitors (NRTI), many of which are substrates of OCT uptake solute carriers (SLC22A) and MATE (SLC47A), P-gp (MDR1, ABCB1), BCRP (ABCG2), or MRP2 (ABCC2) efflux transporters. The aim of this study was to evaluate the inhibitory potential of efavirenz towards these transporters and investigate its effects on the pharmacokinetics and tissue distribution of a known Oct/Mate substrate, lamivudine, in rats. Accumulation and transport assays showed that efavirenz inhibits the uptake of metformin by OCT1-, OCT2- and MATE1-expressing MDCK cells and reduces transcellular transport of lamivudine across OCT1/OCT2- and MATE1-expressing MDCK monolayers. Only negligible inhibition of MATE2-K was observed in HEK-MATE2-K cells. Efavirenz also reduced the efflux of calcein from MDCK-MRP2 cells, but had a rather weak inhibitory effect on Hoechst 33342 accumulation in MDCK-MDR1 and MDCK-BCRP cells. An in vivo pharmacokinetic interaction study in male Wistar rats revealed that intravenous injection of efavirenz or the control Oct/Mate inhibitor cimetidine significantly reduced the recovery of lamivudine in urine and greatly increased lamivudine retention in the renal tissue. Co-administration with efavirenz or cimetidine also increased the AUC(0-∞) value and reduced total body clearance of lamivudine. These data suggest that efavirenz is a potent inhibitor of OCT/Oct and MATE/Mate transporters. Consequently, it can engage in drug-drug interactions that reduce renal excretion of co-administered substrates and enhance their retention in the kidneys, potentially compromising therapeutic safety. Public Library of Science 2018-08-16 /pmc/articles/PMC6095608/ /pubmed/30114293 http://dx.doi.org/10.1371/journal.pone.0202706 Text en © 2018 Ceckova et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Ceckova, Martina Reznicek, Josef Deutsch, Birgit Fromm, Martin F. Staud, Frantisek Efavirenz reduces renal excretion of lamivudine in rats by inhibiting organic cation transporters (OCT, Oct) and multidrug and toxin extrusion proteins (MATE, Mate) |
title | Efavirenz reduces renal excretion of lamivudine in rats by inhibiting organic cation transporters (OCT, Oct) and multidrug and toxin extrusion proteins (MATE, Mate) |
title_full | Efavirenz reduces renal excretion of lamivudine in rats by inhibiting organic cation transporters (OCT, Oct) and multidrug and toxin extrusion proteins (MATE, Mate) |
title_fullStr | Efavirenz reduces renal excretion of lamivudine in rats by inhibiting organic cation transporters (OCT, Oct) and multidrug and toxin extrusion proteins (MATE, Mate) |
title_full_unstemmed | Efavirenz reduces renal excretion of lamivudine in rats by inhibiting organic cation transporters (OCT, Oct) and multidrug and toxin extrusion proteins (MATE, Mate) |
title_short | Efavirenz reduces renal excretion of lamivudine in rats by inhibiting organic cation transporters (OCT, Oct) and multidrug and toxin extrusion proteins (MATE, Mate) |
title_sort | efavirenz reduces renal excretion of lamivudine in rats by inhibiting organic cation transporters (oct, oct) and multidrug and toxin extrusion proteins (mate, mate) |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095608/ https://www.ncbi.nlm.nih.gov/pubmed/30114293 http://dx.doi.org/10.1371/journal.pone.0202706 |
work_keys_str_mv | AT ceckovamartina efavirenzreducesrenalexcretionoflamivudineinratsbyinhibitingorganiccationtransportersoctoctandmultidrugandtoxinextrusionproteinsmatemate AT reznicekjosef efavirenzreducesrenalexcretionoflamivudineinratsbyinhibitingorganiccationtransportersoctoctandmultidrugandtoxinextrusionproteinsmatemate AT deutschbirgit efavirenzreducesrenalexcretionoflamivudineinratsbyinhibitingorganiccationtransportersoctoctandmultidrugandtoxinextrusionproteinsmatemate AT frommmartinf efavirenzreducesrenalexcretionoflamivudineinratsbyinhibitingorganiccationtransportersoctoctandmultidrugandtoxinextrusionproteinsmatemate AT staudfrantisek efavirenzreducesrenalexcretionoflamivudineinratsbyinhibitingorganiccationtransportersoctoctandmultidrugandtoxinextrusionproteinsmatemate |